Get the Stockscreener App
28.70
1.27%
-0.37
After Hours:
28.72
0.02
+0.07%
Royalty Pharma Plc stock is traded at $28.70, with a volume of 1.86M.
It is down -1.27% in the last 24 hours and up +5.90% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$29.07
Open:
$29.03
24h Volume:
1.86M
Relative Volume:
0.77
Market Cap:
$12.86B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
255.11
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
-1.14%
1M Performance:
+5.90%
6M Performance:
-3.50%
1Y Performance:
-1.27%
1-Day Range:
$28.61
$29.12
1-Week Range:
$28.61
$29.36
52-Week Range:
$25.20
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
New South Capital Management Inc. Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Torray Investment Partners LLC Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - Yahoo Finance
143,912 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Hohimer Wealth Management LLC - MarketBeat
Watkins Advises Ascendis Pharma in US$150 Million Royalty Financing - Latham & Watkins LLP -
Regal Partners Ltd Purchases 217,774 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com Australia
Ascendis Pharma secures $150 million royalty deal for YORVIPATH - Investing.com India
Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com Canada
Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com UK
Ascendis Pharma, Royalty Pharma enter $150M royalty funding deal - TipRanks
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement - StockTitan
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - The Bakersfield Californian
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - GlobeNewswire
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - StockTitan
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - Yahoo Finance UK
Bank of New York Mellon Corp Purchases 86,248 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Panagora Asset Management Inc. Sells 129,378 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Searle & CO. Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Lifted to Buy at StockNews.com - MarketBeat
Royalty Pharma plc (RPRX) is looking forward to a strong quarter - SETE News
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference - StockTitan
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt - Simply Wall St
(RPRX) On The My Stocks Page - Stock Traders Daily
Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Yahoo Finance UK
Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Insider Monkey
Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sees Strong Trading Volume - Defense World
Overbrook Management Corp Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Envestnet Portfolio Solutions Inc. Acquires Shares of 9,616 Royalty Pharma plc (NASDAQ:RPRX) - Defense World
SG Americas Securities LLC Sells 88,380 Shares of Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Envestnet Portfolio Solutions Inc. Invests $254,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Lowered to Hold at StockNews.com - Defense World
Raymond James & Associates Has $19.35 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Raymond James & Associates Has $19.35 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Jim Cramer’s Latest Lightning Round: Top 10 Stocks - Insider Monkey
StockNews.com Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading Volume - MarketBeat
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating (NASDAQ:RPRX) - Seeking Alpha
Sumitomo Mitsui Trust Holdings Inc. Buys 62,218 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Sumitomo Mitsui Trust Holdings Inc. Has $26.20 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? - Insider Monkey
Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? - Yahoo Finance
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Swedbank AB - MarketBeat
10 Best Defensive Stocks To Buy Now - Insider Monkey
First Week of April 2025 Options Trading For Royalty Pharma (RPRX) - Nasdaq
The Goldman Sachs Group Increases Royalty Pharma (NASDAQ:RPRX) Price Target to $51.00 - Defense World
Cwm LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Announces Quarterly Dividend of $0.21 - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Receives $42.00 Average Price Target from Brokerages - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RIGGS RORY B | Director |
Jan 02 '24 |
Sale |
28.52 |
235,200 |
6,707,081 |
254,899 |
| RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
| RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
| Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
| Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
| Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
| Avara Management Ltd | 10% Owner |
Dec 15 '23 |
Sale |
28.01 |
10,229 |
286,499 |
2,794,915 |
| Avara Management Ltd | 10% Owner |
Dec 14 '23 |
Sale |
28.91 |
364,441 |
10,534,276 |
2,805,144 |
| Avara Management Ltd | 10% Owner |
Dec 13 '23 |
Sale |
28.95 |
307,935 |
8,916,012 |
3,169,585 |
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):